Fabrice Egros - Aug 18, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Aug 18, 2021
Transactions value $
-$123,124
Form type
4
Date filed
8/20/2021, 04:32 PM
Previous filing
May 20, 2021
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $123K +15.6K +97.72% $7.88 31.6K Aug 18, 2021 Direct
transaction SNDX Common Stock Sale -$246K -15.6K -49.42% $15.75 16K Aug 18, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -15.6K -100% $0.00* 0 Aug 18, 2021 Common Stock 0 $7.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 77,682 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $15.58 to $15.94.
F3 This option is fully vested.